About ADC Therapeutics SA (ADCT)

ADC Therapeutics SA (ADCT) is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. The company’s pipeline includes several product candidates targeting different types of cancer, with a focus on hematological malignancies and solid tumors. ADCT’s lead product candidate is loncastuximab tesirine (Lonca), which is being developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The drug has shown promising results in clinical trials and is currently in the process of seeking regulatory approval. ADCT is also developing several other ADC product candidates, including candidates targeting Hodgkin lymphoma, multiple myeloma, and solid tumors such as gastric cancer and liver cancer.

ADC Therapeutics has entered into strategic partnerships with several pharmaceutical companies to further expand its pipeline and accelerate the development of its ADC technology. The company has collaborations with major players in the pharmaceutical industry, including AstraZeneca and Genmab, which provide financial support and expertise in drug development. These partnerships not only provide funding for the company’s research and development efforts but also validate the potential of ADCT’s technology platform. ADCT’s ADC technology combines monoclonal antibodies with potent cytotoxic agents to selectively target and kill cancer cells while minimizing damage to healthy cells. This targeted approach has the potential to improve the efficacy and safety of cancer treatments, offering new options for patients with limited treatment options.